Does obesity affect outcomes of treatment for lumbar stenosis and degenerative spondylolisthesis? Analysis of the Spine Patient Outcomes Research Trial (SPORT) - Spinal DISC Center | Kris Radcliff, MD | New Jersey
Dr. Kris Radcliff specializes in simplifying the management of complex spine conditions and traumatic spine injuries, focusing exclusively on spine surgery, with particular expertise in the area of artificial disc replacement. Dr. Radcliff is highly experienced, having performed more than 10,000 spine surgeries. He combines conservative decision-making judgment with state-of-the-art and minimally invasive surgical techniques, endoscopic spine surgery, and artificial disc replacement.
Dr. Kris Radcliff, Kris Radcliff MD, Kris Radcliff, spinal disc center, spinal disc center new jersey, artificial disc replacement, artificial disc replacement specialist, endoscopic spine surgeon, endoscopic spine surgeon new jersey, new jersey spine surgeon, best spine surgeon in new jersey, minimally invasive spine surgery, MISS New Jersey, cervical spine surgery, cervical lamino-foraminatomy, cervical radiculopathy, artificial cervical disc replacement, anterior cervical discectomy and fusion, posterior cervical discectomy and fusion, lumbar microdiscectomy, lumbar laminectomy, minimally invasive tlif, ALIF, kyphoplasty, SI joint fusion, facet joint injections, treatment for neck pain, treatment for back pain, treatment for cervical myelopathy, treatment for cervical radiculopathy, treatment for cervical stenosis, treatment for compression fractures, treatment for degenerative disc disease, treatment for herniated disc, treatment for sciatica, treatment for si joint disorders, treatment for spinal stenosis
16767
post-template-default,single,single-post,postid-16767,single-format-standard,bridge-core-3.3,wp-schema-pro-2.7.23,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-30.8.3,qode-theme-bridge,disabled_footer_bottom,qode_advanced_footer_responsive_1000,wpb-js-composer js-comp-ver-7.9,vc_responsive,elementor-default,elementor-kit-16783
 

Does obesity affect outcomes of treatment for lumbar stenosis and degenerative spondylolisthesis? Analysis of the Spine Patient Outcomes Research Trial (SPORT)

Jeffrey A Rihn, Kristen Radcliff, Alan S Hilibrand, David T Anderson, Wenyan Zhao, Jon Lurie, Alexander R Vaccaro, Mitch K Freedman, Todd J Albert, James N Weinstein: Does obesity affect outcomes of treatment for lumbar stenosis and degenerative spondylolisthesis? Analysis of the Spine Patient Outcomes Research Trial (SPORT). In: Spine (Phila Pa 1976), vol. 37, no. 23, pp. 1933–1946, 2012, ISSN: 1528-1159.

Abstract

STUDY DESIGN: Retrospective subgroup analysis of prospectively collected data according to treatment received.

OBJECTIVE: The purpose of this study was to determine whether obesity affects treatment outcomes for lumbar stenosis (SpS) and degenerative spondylolisthesis (DS).

SUMMARY OF BACKGROUND DATA: Obesity is thought to be associated with increased complications and potentially less favorable outcomes after the treatment of degenerative conditions of the lumbar spine. This, however, remains a matter of debate in the existing literature.

METHODS: An as-treated analysis was performed on patients enrolled in the Spine Patient Outcomes Research Trial for the treatment of SpS or DS. A comparison was made between patients with a body mass index (BMI) of less than 30 ("nonobese," n = 373 SpS and 376 DS) and those with a BMI of 30 or more ("obese," n = 261 SpS and 225 DS). Baseline patient characteristics, intraoperative data, and complications were documented. Primary and secondary outcomes were measured at baseline and regular follow-up time intervals up to 4 years. The difference in improvement over baseline between surgical and nonsurgical treatment (i.e., treatment effect) was determined at each follow-up interval for the obese and nonobese groups.

RESULTS: At 4-year follow-up, operative and nonoperative treatment provided improvement in all primary outcome measures over baseline in patients with BMI of less than 30 and 30 or more. For patients with SpS, there were no differences in the surgical complication or reoperation rates between groups. Patients with DS with BMI of 30 or more had a higher postoperative infection rate (5% vs. 1%, P = 0.05) and twice the reoperation rate at 4-year follow-up (20% vs. 11%, P = 0.01) than those with BMI of less than 30. At 4 years, surgical treatment of SpS and DS was equally effective in both BMI groups in terms of the primary outcome measures, with the exception that obese patients with DS had less improvement from baseline in the 36-Item Short Form Health Survey (SF-36) physical function score than nonobese patients (22.6 vs. 27.9, P = 0.022). With nonoperative treatment, patients with SpS with BMI of 30 or more did worse in regard to all 3 primary outcome measures, and patients with DS with BMI of 30 or more had similar SF-36 bodily pain scores but less improvement over baseline in the SF-36 physical function and Oswestry Disability Index scores. Treatment effects for SpS and DS were significant within each BMI group for all primary outcome measures in favor of surgery. Obese patients had a significantly greater treatment effect than nonobese patients with SpS (Oswestry Disability Index, P = 0.037) and DS (SF-36 PF, P = 0.004) largely due to the relatively poor outcome of nonoperative treatment in obese patients.

CONCLUSION: Obesity does not affect the clinical outcome of operative treatment of SpS. There are higher rates of infection and reoperation and less improvement from baseline in the SF-36 physical function score in obese patients after surgery for DS. Nonoperative treatment may not be as effective in obese patients with SpS or DS.

BibTeX (Download)

@article{pmid22614793,
title = {Does obesity affect outcomes of treatment for lumbar stenosis and degenerative spondylolisthesis? Analysis of the Spine Patient Outcomes Research Trial (SPORT)},
author = {Jeffrey A Rihn and Kristen Radcliff and Alan S Hilibrand and David T Anderson and Wenyan Zhao and Jon Lurie and Alexander R Vaccaro and Mitch K Freedman and Todd J Albert and James N Weinstein},
doi = {10.1097/BRS.0b013e31825e21b2},
issn = {1528-1159},
year  = {2012},
date = {2012-11-01},
urldate = {2012-11-01},
journal = {Spine (Phila Pa 1976)},
volume = {37},
number = {23},
pages = {1933--1946},
abstract = {STUDY DESIGN: Retrospective subgroup analysis of prospectively collected data according to treatment received.

OBJECTIVE: The purpose of this study was to determine whether obesity affects treatment outcomes for lumbar stenosis (SpS) and degenerative spondylolisthesis (DS).

SUMMARY OF BACKGROUND DATA: Obesity is thought to be associated with increased complications and potentially less favorable outcomes after the treatment of degenerative conditions of the lumbar spine. This, however, remains a matter of debate in the existing literature.

METHODS: An as-treated analysis was performed on patients enrolled in the Spine Patient Outcomes Research Trial for the treatment of SpS or DS. A comparison was made between patients with a body mass index (BMI) of less than 30 ("nonobese," n = 373 SpS and 376 DS) and those with a BMI of 30 or more ("obese," n = 261 SpS and 225 DS). Baseline patient characteristics, intraoperative data, and complications were documented. Primary and secondary outcomes were measured at baseline and regular follow-up time intervals up to 4 years. The difference in improvement over baseline between surgical and nonsurgical treatment (i.e., treatment effect) was determined at each follow-up interval for the obese and nonobese groups.

RESULTS: At 4-year follow-up, operative and nonoperative treatment provided improvement in all primary outcome measures over baseline in patients with BMI of less than 30 and 30 or more. For patients with SpS, there were no differences in the surgical complication or reoperation rates between groups. Patients with DS with BMI of 30 or more had a higher postoperative infection rate (5% vs. 1%, P = 0.05) and twice the reoperation rate at 4-year follow-up (20% vs. 11%, P = 0.01) than those with BMI of less than 30. At 4 years, surgical treatment of SpS and DS was equally effective in both BMI groups in terms of the primary outcome measures, with the exception that obese patients with DS had less improvement from baseline in the 36-Item Short Form Health Survey (SF-36) physical function score than nonobese patients (22.6 vs. 27.9, P = 0.022). With nonoperative treatment, patients with SpS with BMI of 30 or more did worse in regard to all 3 primary outcome measures, and patients with DS with BMI of 30 or more had similar SF-36 bodily pain scores but less improvement over baseline in the SF-36 physical function and Oswestry Disability Index scores. Treatment effects for SpS and DS were significant within each BMI group for all primary outcome measures in favor of surgery. Obese patients had a significantly greater treatment effect than nonobese patients with SpS (Oswestry Disability Index, P = 0.037) and DS (SF-36 PF, P = 0.004) largely due to the relatively poor outcome of nonoperative treatment in obese patients.

CONCLUSION: Obesity does not affect the clinical outcome of operative treatment of SpS. There are higher rates of infection and reoperation and less improvement from baseline in the SF-36 physical function score in obese patients after surgery for DS. Nonoperative treatment may not be as effective in obese patients with SpS or DS.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
No Comments

Sorry, the comment form is closed at this time.